Lite Strategy, Inc.
LITSNasdaq
$0.99
↑ +1.7%Jul 17 close · end-of-day
Price
1Y↓ -74.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$35.2M
Enterprise Value
$27.7M
P/E
—
P/S
—
P/B
0.6
EV/EBITDA
—
PEG
—
FCF Yield
-59.2%
Dividend Yield
—
Revenue (TTM)
$0.00
Net Income (TTM)
-$60.8M
Free Cash Flow (TTM)
-$20.8M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-107.0%
ROIC
-93.1%
Debt / Equity
—
Net Cash
$7.5M
Return 1Y
-78.1%
Company profile
MEI Pharma, Inc. focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trials for patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex in Phase I clinical trial for human epidermal growth factor receptor 2 negative breast cancer.
- CEO
- Daniel P. Gold
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 100
- Headquarters
- California
- Website
- meipharma.com
Earnings
LITS Q3 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.66↑ +69.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $34.8M | $40.7M | $48.8M | $65.3M | $0.00 |
| Gross profit | — | — | — | — | — |
| Operating income | -$60.4M | -$75.5M | -$36.8M | $14.5M | -$17.5M |
| Net income | -$41.0M | -$54.0M | -$32.0M | $17.8M | -$15.9M |
| Diluted EPS | -$0.60 | -$9.99 | -$4.78 | $2.67 | -$2.39 |
| Operating cash flow | -$32.0M | -$48.7M | -$52.5M | -$50.5M | -$20.8M |
| Free cash flow | -$32.7M | -$49.2M | -$52.5M | -$50.5M | -$20.8M |
| Gross margin | — | — | — | — | — |
| Operating margin | -173.7% | -185.5% | -75.3% | 22.3% | — |
| Net margin | -117.8% | -132.7% | -65.6% | 27.2% | — |
| Line item | Q4 '24 | Q1 '24 | Q2 '24 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '25 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$19.0M | -$8.4M | -$3.5M | -$2.8M | -$2.9M | -$3.7M | -$29.9M | -$21.6M |
| Net income | -$18.4M | -$8.0M | -$2.7M | -$2.6M | -$2.7M | -$3.6M | -$30.8M | -$23.7M |
| Diluted EPS | -$2.76 | -$1.20 | -$0.40 | -$0.39 | -$0.40 | -$0.12 | -$0.82 | -$0.66 |
| Operating cash flow | -$18.0M | -$11.4M | -$3.7M | -$3.3M | -$2.5M | -$4.5M | -$1.9M | -$1.5M |
| Free cash flow | -$18.0M | — | — | -$3.3M | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 23, 2026
Jun 18, 2026
Apr 25, 2026
Aug 28, 2025
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-24 | Flynn James P | Buy | 25,000 | $0.86 | $21,387.50 | filing |
| 2025-12-19 | Flynn James P | Buy | 70,000 | $1.40 | $97,699.00 | filing |
| 2025-12-18 | Schornstein Alexander | Sale | 690,611 | $1.37 | $946,137.07 | filing |
| 2025-11-19 | Flynn James P | Buy | 12,100 | $1.88 | $22,777.04 | filing |
| 2025-09-30 | Flynn James P | Award | 10,000 | $2.54 | $25,430.00 | filing |
Latest 5 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.